Pluri Inc.
PLUR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.99
KIRA · Stoqly’s AI analyst, in plain words
- Pluri Inc. had $1.0M of revenue in fiscal 2026, down 24.0% on the year before.
- Its operating margin was −2,454.5%, down 794.6 pts: of every 100 in sales, about −2,455 is left after running the business.
- Pluri Inc. lost $23.8M in fiscal 2026.
- Free cash flow was −$20.2M in fiscal 2026, −1,990.3% of revenue.
Market cap
$9.6M
P/E
—
Revenue
$1.0M
Net income
−$23.8M
Free cash flow
−$20.2M
Operating margin
−2,454.5%
Pluri Inc. in 30 seconds · fiscal 2026
Are sales growing?
−24.0%
No. Sales fell 24.0% last year.
Does it make a profit?
−2,344.6%
No. It lost money last year.
Does profit turn into cash?
−1,990.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pluri Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 10, 2026
- Legal name
- Pluri Inc.
- CIK
- 0001158780
Pluri Inc. · PLUR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $0.3M | $0.3M | $1.3M | $1.0M |
| Revenue growth | — | 22.6% | 13.6% | 309.8% | −24.0% |
| Gross margin | 100.0% | 96.9% | 98.8% | 49.0% | 44.6% |
| Operating margin | −17,774.8% | −9,493.4% | −6,796.9% | −1,659.9% | −2,454.5% |
| Net income | −$41.2M | −$28.3M | −$20.9M | −$22.6M | −$23.8M |
| Net margin | −17,624.8% | −9,867.9% | −6,407.4% | −1,690.3% | −2,344.6% |
| Diluted EPS | −$1.28 | −$6.24 | −$3.99 | −$3.56 | −$2.44 |
| Cash | |||||
| Cash from operations | −$36.5M | −$22.9M | −$18.0M | −$18.2M | −$19.6M |
| Capital expenditure | $0.3M | $0.3M | $0.3M | $1.6M | $0.6M |
| Free cash flow | −$36.8M | −$23.1M | −$18.3M | −$19.8M | −$20.2M |
| FCF margin | −15,718.4% | −8,055.4% | −5,627.0% | −1,484.2% | −1,990.3% |
| Share count change | 14.5% | −85.8% | 14.4% | 20.9% | 53.8% |
| Debt and strength | |||||
| Cash and short-term investments | $9.8M | $5.4M | $6.8M | $5.9M | $3.5M |
| Shareholders' equity | $30.0M | $13.4M | $0.1M | −$6.8M | −$23.0M |
| Current ratio | 8.5x | 7.4x | 7.0x | 0.7x | 0.3x |
| Interest coverage | −46.9x | −32.3x | −25.6x | −25.4x | −26.8x |
| Returns and quality | |||||
| Return on equity | −94.6% | −130.5% | −310.6% | — | — |
| Return on tangible equity | 137.7% | 216.3% | 5,453,899.0% | — | — |
| Piotroski F-score | — | 4 | 4 | 2 | 2 |
| Altman Z'' | −16.2 | −24.3 | −34.0 | −43.1 | −74.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pluri Inc. · PLUR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.99 a share, the company is worth $9.6M.
Source: SEC EDGAR XBRL filings (CIK 0001158780). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.